Although the precise mechanism of the effects of renal impairment on the nonrenal clearance of brigatinib is unknown, the results of this study provide the scientific basis for appropriate dosage of brigatinib in order to achieve a favorable benefit versus risk profile during treatment of patients with ALK + NSCLC who have severe renal insufficiency. Here, ALK is linked to non-small cell lung carcinoma.